Development of cancer therapeutic technology by functional measurement and control of cell division.

我们已经开发了一种用于癌症早期诊断和治愈监测的技术，使用我们发现的癌症标记物Bradeion。我们还开发了发现抗癌药物的布拉迪恩试验技术。结果，我们成功地开发了癌症诊断系统和试剂盒。此外，我们还成功地对Bradeion进行了结构分析和表征，并通过建立其酶活性的测定方法，成功地开发了测定其抑制效果的技术。在研究的最后一年，我们使用了荧光相关光谱(FCS)来检测患者血清中的单一目标分子。该仪器采用激光共聚焦显微镜，每分钟可测量10pI的血清，每份标本仅需1次。3000个样品可以在一周内测量。在室温下储存一周的样品中，数据是可重现的。在冰箱中保存的样品可以稳定保存一个月。尽管许多蛋白质结构分析项目泛滥，但具有原创性的材料的结构展示终究没有成功。另一方面，我们成功地对癌症标志物Bradeion进行了结构分析，结果我们缩小到只有一种有用的材料，并集中了符合目的的方法学。选择抗癌药物的候选药物，不仅要有药用价值，而且要减少毒性。因此，我们使用了一只果蝇和一只嵌合体小鼠(获得专利)，为毒性检测配备了动物模型。我们从Bradeion蛋白的结构分析中发现了一种抑制剂，并使用FCS进行了高通量筛选。通过对筛选出的候选药物进行评价，并通过动物模型进行毒性检测，旨在开发一种抗癌药物。

We have developed a technology for early diagnosis and cure monitor of cancer with Bradeion, a cancer marker we found. We have also developed the technology of Bradeion assay for discovering anticancer agent. As a result, we succeeded in the development of a cancer diagnosis system and kit. In addition, we succeeded in the structure analysis and the characterization of Bradeion, and development of the technology measuring inhibiting effect by the establishment of the method measuring its enzyme activity. In the last year of the study period, we used a fluorescence correlation spectroscopy (FCS) detecting single target molecule in patient serum. This full automatic machine with confocal laser microscope can measure using 10 pI of serum with a minute, and it costs only \1 per specimen. 3, 000 samples can be measured within one week. The data is reproducible in the samples stored at room temperature for a week. The samples preserved in a refrigerator are stable for a month.The structure presentation of a material with originality did not succeed after all until now, though many projects for protein structure analysis flooded. On the other hand, we succeed in the structure analysis of the cancer marker, Bradeion, as a result that we narrowed down to only one useful material and centralized the methodology that complies with a purpose. It is not only medicinal benefits but also less toxicity that is important to select the candidate of and cancer drug. We therefore equipped animal models for the toxic examination using a Drosophila and a chimera mouse(patented). We investigate an inhibitor from structure analysis of Bradeion protein and perform a high throughput screening using the FCS. We aim at development of an anticancer agent, by performing the evaluation of the candidate selected by the screening and a toxic examination by the animal model.